Clinical Innovations enters China with new Shanghai Subsidiary

Clinical Innovations has launched its new subsidiary in Shanghai to grow in the Chinese labor and delivery market, expanding its global footprint.

Clinical Innovations’ products are available in as many as 90 countries. The Salt Lake City-based obstetric and neonatal care devices producer newly appointed JB Medical Supplies as its Australian distributor and also German company Brenner Medical in the previous year.

Kevin Han, former establisher of Boston Scientific’s Chinese urology and pelvic health unit and head of business unit and commercial head for China and Hong Kong, who has held commercial and channel manager posts in the Chinese operations of Johnson & Johnson Medical and GE earlier, will be managing the company’s newest subsidiary, CI Medical Instruments.

“Creating CI Medical Instruments represents a major milestone for Clinical Innovations, and Kevin is the perfect person to spearhead this new venture,” Steve Cash, Clinical Innovations’ senior vice president of global sales, said in a statement.

Clinical Innovations recently hired Richard Ji, Becton Dickinson’s former vice president of catheter solutions, as its VP of operations to reorganize the company as it aims to spread itself out in the domestic and international markets. Ji was attached to BD since 1995, serving at numerous interanational positions in the company’s manufacturing, research, quality control and supply chain functions.

 “With our mission of helping mothers and babies around the world, it’s critical we continue expanding in regions where we can have a big impact,” said Ken Reali, Clinical Innovations CEO and president. “China is an important, underserved market, and we look forward to meeting its needs with an organization that puts clinicians and families first.”

The post Clinical Innovations enters China with new Shanghai Subsidiary appeared first on Drugdu.com

from Drugdu  https://goo.gl/QgQoHk

Johnson & Johnson Sells Calibra Diabetic Product to Cequr

Johnson & Johnson is moving out from the diabetes business and sold its Calibra product (marketed as OneTouch Via, but never launched) to a 10-year-old company named CeQur, which was already working on a similar insulin-delivery wearable. The terms and conditions of this deal have not yet been yet disclosed, but CeQur has attained an exclusive worldwide license for this technology.

Jay Warner, CeQur’s SVP of commercialization said, “They’re divesting out of the diabetes market and that’s what led us to seek out this asset; We knew they had Calibra in their portfolio and we knew it matched well with our product. And so we decided to go after it.”

Jay Warner stated, “Some people with Type 1 have to change their basal rate daily, [for instance] because they exercise one day and not another day. If you’re altering your basal rate the PAQ isn’t right for you because the PAQ has a fixed basal rate. So for that population, the Calibra product’s ideal; Calibra also adds a simpler transition. There are 3 million people on basal alone and many of those people really need to be on basal-bolus, but they’re avoiding it because they don’t want to inject in public, they don’t want to go into what they call the ‘second injection burden.' And that’s where Calibra is a great way to start patients on a product.”

Robert Farra, CEO of CeQur, said “During mealtime, the patient is able to actuate the buttons to release what we call a bolus injection of insulin. So very discretely, very simply, every time they press the button they get a two-unit insulin dose; A person can do that when they’re among friends, at work, at a restaurant, in a conference room. It really doesn’t matter. They don’t have to excuse themselves and go into a private location to receive their bolus dose of insulin. It happens very discretely and that’s one of the key advantages of our product.”

CeQur plans to introduce its Calibra product with a new brand name in the second quarter of 2019. 

The post Johnson & Johnson Sells Calibra Diabetic Product to Cequr appeared first on Drugdu.com

from Drugdu  https://goo.gl/QgQoHk

Meet Drugdu.com (Ddu) at CPhI China 2017 for Global Business Partners

CPhI China 2017 will be held from 20th June to 22nd June 2017 at the Shanghai New International Expo Center (SNIEC) in Shanghai, China. Ddu, the leading global pharmaceutical and medical device B2B platform, will attend the exhibition with products from high-priority members and launch synchronization services of buy offers an agency service.

Since the launch of CPhI China 16 years ago, CPhI China has developed into one of the world's most comprehensive pharma-focused events. According to the statistics, 75,000 attendees are expected to be present in CPhI along with more than 2,800 exhibitors, representing a mix across all different zones in the pharma value chain. After elaborated preparation, Ddu will once again show itself at CPhI.

Ddu will attend the exhibition with products from high-priority members and offer a full range of online & offline promotion services. Based on its star-studded advertisements, Ddu will present a comprehensive display of the website brand as well as users’ products. At the same time, Ddu will launch the fast matching system, from which buy offers and agent intents will be quickly posted to appropriate partners automatically.

Ddu will launch an App to bring users effective communication and potential partners anytime and anywhere.

Sharing of Sourcing Request in Five Exhibitions

In order to facilitate buyers and suppliers, Ddu will launch the value-added service, from which buy offers and agent intents can be displayed in five exhibitions. For example, users in CPhI Shanghai release the buy offers and agent intents by the scanning code. The buy offers and agent intents will be collected and updated on a live screen. They will also be displayed on the website during the following four exhibitions: INTERPHEX JAPAN, HOSPEX JAPAN, CMEH Shanghai and CEEP Shanghai.

Ddu breaks the limitation of time and space and combines five exhibitions together to realize information sharing. Ddu said, “On the basis of users’ feedback and market research, Ddu come up with this value-added service, in order to make full use of resources, reduce costs and improve business efficiency.”

1^st Anniversary of Ddu Global Promotion Plan

Ddu attended CPhI Shanghai for the first time in June 2016. Ddu global promotion plan was launched at that time. With three to four shows in global exhibitions relating to pharmaceuticals and medical devices, Ddu enables pharmaceuticals and medical devices companies to expand their global business and promote their brand internationalization in a cost-effective way. It has got much attention from the industry. This June, as the 1^st anniversary of Ddu Global Promotion Plan, Ddu will attend CPhI again.  

Ddu Global Promotion Plan has spread to four continents, with over 10 countries and regions. It has gained global attention from hundreds of thousands of people and brought over 10 thousand potential cooperative orders. “It's a milestone and a new start for Ddu as well as the global promotion plan. In the future, Ddu will continue to expand to other countries and regions, helping users save their time and cost”, an official said. There have been more than 10 thousand users on Ddu and Ddu has won a leading place in this area.

The post Meet Drugdu.com (Ddu) at CPhI China 2017 for Global Business Partners appeared first 

on Drugdu.com

from Drugdu  https://goo.gl/QgQoHk